Advertisement

Tumor Biology

, Volume 36, Issue 12, pp 9693–9701 | Cite as

Interaction between microRNA-181a and TNFAIP1 regulates pancreatic cancer proliferation and migration

  • Peng Zhang
  • Zhiyong Guo
  • Ronglin Hu
  • Xiaoshun He
  • Xingyuan Jiao
  • Xiaofeng Zhu
Research Article

Abstract

We investigated the role of microRNA 181a (miR-181a) and its downstream target tumor necrosis factor, alpha-induced protein 1 (TNFAIP1) in pancreatic cancer regulation. Quantitative real-time PCR (qRT-PCR) was applied to evaluate the gene expression of miR-181a in seven pancreatic cancer cell lines. MiR-181a inhibitor lentivirus (miR-181a-IN) was used to down-regulate miR-181a in Capan-1 and AsPC-1 cells. The effects of miR-181a down-regulation on pancreatic cancer were evaluated by in vitro proliferation assay and migration assay. Targeting of miR-181a on TNFAIP1 in pancreatic cancer was evaluated by dual-luciferase reporter assay and western blot. TNFAIP1 was either upregulated by pcDNA3.1 (+) expression vector or down-regulated by siRNA in Capan-1 and AsPC-1 cells. The subsequent effects of TNFAIP1 upregulation or down-regulation on miR-181a mediated pancreatic cancer regulation were also evaluated through in vitro proliferation and migration assays. The in vivo effect of miR-181a down-regulation on pancreatic tumor growth was evaluated by a xenograft assay. MiR-181a was consistently upregulated in pancreatic cancer cell lines. MiR-181a down-regulation inhibited proliferation and migration in vitro, and upregulated TNFAIP1 in pancreatic cancer cells. Ectopic TNFAIP1 overexpression had similar tumor-suppressive effects on pancreatic cancer proliferation and migration as miR-181a down-regulation, whereas siRNA-mediated TNFAIP1 down-regulation had opposite or oncogenic effects on pancreatic cancer. In vivo pancreatic xenograft showed miR-181a recapitulated the in vitro anti-tumor effects and its regulation on TNFAIP1. MiR-181a played a critical role in regulating pancreatic cancer growth and migration, likely interacting with TNFAIP1.

Keywords

Pancreatic cancer miR-181a TNFAIP1 Tumor proliferation Migration 

Notes

Conflicts of interest

None

Funding

This work was funded by the National Natural Science Foundation of China (No. 81270531) and Doctoral Program Foundation of Institutions of Higher Education of China (No. 20120171110073).

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Williamson RC. Pancreatic cancer: the greatest oncological challenge. Br Med J. 1988;296(6620):445–6.CrossRefGoogle Scholar
  3. 3.
    Safioleas MC, Moulakakis KG. Pancreatic cancer today. Hepato-Gastroenterology. 2004;51(57):862–8.PubMedGoogle Scholar
  4. 4.
    Capurso G, Festa S, Valente R, Piciucchi M, Panzuto F, Jensen RT, et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol. 2012;49(1):R37–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Pillai RS. MicroRNA function: multiple mechanisms for a tiny RNA? RNA. 2005;11(12):1753–61.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. BioMed Res Int. 2015;2015:125094.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Zaravinos A. The regulatory role of microRNAs in EMT and cancer. J Oncol. 2015;2015:865816.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yang CC, Hung PS, Wang PW, Liu CJ, Chu TH, Cheng HW, et al. miR-181 as a putative biomarker for lymph-node metastasis of oral squamous cell carcinoma. J Oral Pathol Med Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol. 2011;40(5):397–404.Google Scholar
  9. 9.
    Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharma Biomed Pharm. 2010;64(6):399–408.CrossRefGoogle Scholar
  10. 10.
    Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 2010;57(3):264–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med. 2012;30(3):680–6.PubMedGoogle Scholar
  12. 12.
    Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010;70(5):1793–803.CrossRefPubMedGoogle Scholar
  13. 13.
    Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008;1236:185–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, et al. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012;33(7):1294–301.CrossRefPubMedGoogle Scholar
  15. 15.
    Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP. TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest. 2013;123(1):150–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer J Int du Cancer. 2007;120(5):1046–54.CrossRefGoogle Scholar
  18. 18.
    Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Frontiers Bioscience A J Virtual Lib. 2008;13:5094–107.CrossRefGoogle Scholar
  19. 19.
    Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Kim DM, Chung KS, Choi SJ, Jung YJ, Park SK, Han GH, et al. RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells. Int J Cancer J Int du Cancer. 2009;125(11):2520–7.CrossRefGoogle Scholar
  21. 21.
    Zhang CL, Wang C, Yan WJ, Gao R, Li YH, Zhou XH. Knockdown of TNFAIP1 inhibits growth and induces apoptosis in osteosarcoma cells through inhibition of the nuclear factor-kappaB pathway. Oncol Rep. 2014;32(3):1149–55.PubMedGoogle Scholar
  22. 22.
    Zhang X, Li X, Tan Z, Liu X, Yang C, Ding X, et al. MicroRNA-373 is upregulated and targets TNFAIP1 in human gastric cancer, contributing to tumorigenesis. Oncology letters. 2013;6(5):1427–34.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Zhou C, Li X, Zhang X, Liu X, Tan Z, Yang C, et al. microRNA-372 maintains oncogene characteristics by targeting TNFAIP1 and affects NFkappaB signaling in human gastric carcinoma cells. Int J Oncol. 2013;42(2):635–42.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Organ Transplant Center, The First Affiliated HospitalSun Yat-sen UniversityGuangzhouChina

Personalised recommendations